India Approves First Dengue Vaccine Qdenga: Game-Changing Prevention for 4-60 Year Age Group

India has approved its first dengue vaccine, with the Drug Controller General of India (DCGI) granting market authorisation to Takeda Biopharmaceuticals’ Qdenga for the prevention of dengue in individuals aged four to sixty years. This landmark regulatory decision represents a transformative moment in India’s public health strategy, offering hope to a nation grappling with exponential growth in dengue infections over the past two decades.

Qdenga is a tetravalent, live-attenuated vaccine designed to provide protection against all four dengue virus serotypes and is administered as two subcutaneous doses of 0.5 mL each, given three months apart. The vaccine was approved for use in individuals regardless of previous dengue exposure, without the need for pre-vaccination testing, significantly simplifying vaccination logistics and expanding accessibility.

The approval arrives at a critical juncture for Indian public health. Reported dengue cases in India have increased 11-fold in the past two decades, overwhelming healthcare systems and placing extraordinary burden on already-strained medical infrastructure. Dengue’s expansion reflects converging factors including rising temperatures facilitating mosquito proliferation, densely populated urban environments, and inadequate vector control mechanisms unable to contain disease transmission.

The approval follows recommendations made earlier this year by the Subject Expert Committee (SEC) on Vaccines under the Central Drugs Standard Control Organisation (CDSCO), after reviewing Indian clinical trial data alongside extensive global evidence. Regulatory authorities based their decision on comprehensive clinical assessments establishing vaccine safety, efficacy, and appropriate dosing for the targeted population.

The vaccine’s global track record provides substantial reassurance regarding its safety profile and effectiveness. Qdenga is approved in 42 countries, including the European Union, the United Kingdom, Switzerland and Indonesia, with over 24 million doses distributed without major safety issues. Takeda’s global clinical development programme included 19 Phase I, II and III clinical trials involving more than 28,000 participants across dengue-endemic and non-endemic regions.

Manufacturing partnerships will prove crucial for achieving population-level vaccine availability. Takeda has a collaboration with Indian vaccine maker Biological E aimed at expanding the vaccine’s manufacturing, positioning India to potentially achieve vaccine self-sufficiency while supporting regional dengue prevention efforts across endemic nations. This domestic manufacturing capacity strengthens India’s vaccine security while reducing dependence on international supply chains.

Since 2023, WHO’s Strategic Advisory Group of Experts on Immunization (SAGE) endorsed the use of TAK-003 without the need for pre-vaccination screening, with the vaccine subsequently recommended by WHO for use in dengue-endemic settings, supporting its introduction in public immunization programs. This international validation reinforces India’s regulatory decision while facilitating potential integration into government vaccination programs.

The vaccine’s impact will depend substantially on effective implementation strategies. Healthcare authorities must establish efficient distribution networks, train medical personnel in vaccination protocols, conduct public awareness campaigns, and address vaccine hesitancy through transparent communication about safety and efficacy. Equitable access will determine whether dengue prevention becomes privilege of affluent populations or truly universal public health intervention.

As dengue continues devastating vulnerable communities disproportionately affected by mosquito-borne infections, India’s approval of Qdenga represents tangible progress toward controlling a disease that has placed extraordinary strain on the nation’s health systems for decades.